Skin Diseases, Bacterial  >>  Cubicin (daptomycin)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
NCT01551719: Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation

Withdrawn
N/A
0
Europe
Implemented procedure, MIC/Breakpoint ratio and tissue penetration for available antibiotics e.g., - Semisynthetic Penicillins, - Cephalosporins, - Linezolid, - Vancomycin, - Daptomycin, - Teicoplanin, - Tigecycline
Federico II University
Infection of Skin and/or Subcutaneous Tissue
03/13
03/13

Download Options